People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

18 Sep 2020
Change (% chg)

$0.22 (+3.06%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rowland, Lloyd 

Mr. Lloyd A. Rowland is Senior Vice President, Chief Compliance Officer, General Counsel, Secretary of the Company. Mr. Rowland brings 25 years of biotechnology and pharmaceutical industry legal counsel and transactional experience to CytomX. From August 2014 until February 2017, Mr. Rowland held the position of senior vice president, general counsel, secretary and chief compliance officer of Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Prior to Xencor, Mr. Rowland, over a twelve-year career at Amylin Pharmaceuticals, held various roles, most recently as vice president and chief compliance officer and formerly, as vice president, general counsel and secretary. During his time as general counsel at Amylin, he directed all corporate legal and compliance affairs for the company including the launch of two pharmaceutical products. Prior to joining Amylin, Mr. Rowland served as vice president, secretary and general counsel for Alliance Pharmaceutical Corp. Mr. Rowland received his B.S. degree in economics and political science from Southern Methodist University, and his J.D. from Emory University School of Law.

Basic Compensation

Total Annual Compensation, USD 390,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 707,843
Fiscal Year Total, USD 1,097,840

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Sean McCarthy


Carlos Campoy


Amy Peterson


W. Michael Kavanaugh


Lloyd Rowland


Nick Galli

As Of  31 Dec 2019